European Commission logo
English English
CORDIS - EU research results
CORDIS

Rapid therapy development through Open nCoronavirus Vaccine Platform

Deliverables

Project risk management plan

This deliverable will outline the procedures for risk monitoring and evaluation throughout the project and include a risk register.

Evaluation of immunogenicity of all candidates

All vaccine candidates have been evaluated and if working, also tested for immunogenicity in mouse and rabbit studies. The samples have been analyzed.

Interim Activity Report

Delivery of Interim Activity report for Month 1-6

Synthesis of vaccine candidates, proteins and peptides

All vaccine candidates, proteins and produced and delivered to KI

Documentation for EMA

Provide complete documentation of the Cliniporator to the EMA/MPA for use in delivery of plasmid DNA vaccines in humans

GMP manufactured aseptically filled plasmid drug product

Dispensing of the vaccine candidate

Protocol for neutralization assay

Established assay for determination of neutralizing antibodies to SARS-COV-2 that can be used to test mouse and rabbit sera

Selection of the best vaccine candidate for GMP and tox studies

One vaccine candidate has been selected based on safety and immunogenicity for production according to GMP and GLP toxicology testing.

A single step delivery procedure

Develop a device that is added to the Cliniporation electrode handle that enables injection of DNA and in vivo electroporation in a single step. This may or may not be used in the clinical trial depending on requirements from the EMA/MPA.

Communication and Dissemination Plan

Establish a Communication and Dissemination Plan

Assays to measure cytokine induction and IFN supression

Primers, RT-qPCR assays, transfection protocols, control constructs, transfection protocols, reporter assays

Report writing for the IMPD, month

A written report of the toxicological evaluation of the vaccine candidate according to GLPto be submitted to EMAMPA

Pre-Production Evaluation and plasmid production for toxicology studies

Complete study report on the manufacturing system performance and plasmid production for toxicological evaluation.

Consortium secured intranet and Management handbook

These tools will facilitate communication and establish the principles of work within the consortium. The Management Handbook will contain all internal consortium agreement related rules (for publication, etc.), key contact and info to use the intranet, plus a “digest” of H2020 rules easier to understand for SMEs and advices adapted to the consortium.

A locked Cliniporator with pulse pattern for plasmid DNA delivery

Establishment of a pulse pattern for in vivo electroporation that is optimized for delivery of plasmid DNA

Assessment of cytokine induction and IFN suppression by first set of vaccine candidates

Statistically robust data on upregulation of IFN-beta, IFN-lambda 1 and 2, IL-6, IL-8, TNF-alpha, CCL4, CCL5, CXCL10. Statistically robust data on dysregulation of IFN-beta induction or IFN signaling

Completion of the GLP toxicity study, month

Completed toxicological evaluation according to GLP of the vaccine candidate

Challenge protocol

Established protocol for infecting mice with SARS-COV-2 before or completed vaccinations

Publications

A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells

Author(s): Sofia Appelberg Gustaf Ahlén Jingyi Yan Negin Nikouyan Sofie Weber Olivia Larsson Urban Höglund Soo Aleman Friedemann Weber Emma Perlhamre Johanna Apro Eva-Karin Gidlund Ola Tuvesson Simona Salati Matteo Cadossi Hanna Tegel Sophia Hober Lars Frelin Ali Mirazimi Matti Sällberg
Published in: EMBO Molecular Medicine, Issue 17574684, 2022, ISSN 1757-4684
Publisher: EMBO Press
DOI: 10.15252/emmm.202215821

Inhibition of SARS–CoV-2 by type I and type III interferons

Author(s): Ulrike Felgenhauer, Andreas Schoen, Hans Henrik Gad, Rune Hartmann, Andreas R. Schaubmar, Klaus Failing, Christian Drosten, Friedemann Weber
Published in: Journal of Biological Chemistry, Issue 295/41, 2020, Page(s) 13958-13964, ISSN 0021-9258
Publisher: American Society for Biochemistry and Molecular Biology Inc.
DOI: 10.1074/jbc.ac120.013788

Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease

Author(s): Jingyi Yan Chandrashekar Ravenna Bangalore Negin Nikouyan Sofia Appelberg Daniela Nacimento Silva Haidong Yao Anna Pasetto Friedemann Weber Sofie Weber Olivia Larsson Urban Höglund Gordana Bogdanovic Malin Grabbe Soo Aleman Laszlo Szekely Attila Szakos Ola Tuvesson Eva-Karin Gidlund Matteo Cadossi Simona Salati Matti Sällberg
Published in: Molecular Therapy, Issue Volume 32, Issue 2, 7 February 2024, 2024, Page(s) Pages 540-555, ISSN 1525-0016
Publisher: Nature Publishing Group
DOI: 10.1016/j.ymthe.2024.01.007

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine

Author(s): Gustaf Ahlén, Lars Frelin, Negin Nikouyan, Friedemann Weber, Urban Höglund, Olivia Larsson, Marie Westman, Ola Tuvesson, Eva-karin Gidlund, Matteo Cadossi, Sofia Appelberg, Ali Mirazimi, Matti Sällberg
Published in: Journal of Virology, Issue 94/18, 2020, ISSN 0022-538X
Publisher: American Society for Microbiology
DOI: 10.1128/jvi.01279-20

Imaging of SARS-CoV-2 infected Vero E6 cells by helium ion microscopy

Author(s): Natalie Frese, Patrick Schmerer, Martin Wortmann, Matthias Schürmann, Matthias König, Michael Westphal, Friedemann Weber, Holger Sudhoff, Armin Gölzhäuser
Published in: Beilstein Journal of Nanotechnology, Issue 12, 2021, Page(s) 172-179, ISSN 2190-4286
Publisher: Beilstein-Institut Zur Forderung der Chemischen Wissenschaften
DOI: 10.3762/bjnano.12.13

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available